# Observational study of Reflux-related findings at distal esophagus, gastric pouch, and anastomotic site one and three years after one-anastomosis gastric bypass: exploring the diagnostic accuracy of endoscopy compared to biopsy

**Authors:** Mohamed Hany, Eman Sheta, Walid El Ansari

PMC · DOI: 10.1186/s12876-025-04510-w · BMC Gastroenterology · 2025-12-18

## TL;DR

This study compares endoscopy and biopsy for detecting reflux-related issues in patients who had gastric bypass surgery, finding that endoscopy's accuracy varies by location and time.

## Contribution

The study provides new insights into the diagnostic accuracy of endoscopy versus biopsy at different anatomical sites and time points after gastric bypass surgery.

## Key findings

- UE reliably detected distal esophageal disease but struggled to exclude it, while it accurately identified and ruled out disease at the gastric pouch.
- At the anastomotic site, UE findings closely mirrored biopsy results, suggesting UE can substitute for biopsy when it is unavailable.
- The incidence of normal UE findings at the distal esophagus increased significantly over time, while abnormalities increased at the gastric pouch and anastomotic site.

## Abstract

We aimed to compare upper endoscopy (UE) with histopathology (biopsy) for detecting reflux-related findings at 1 and 3 years following one-anastomosis gastric bypass (OAGB).

This retrospective analysis included 150 OAGB patients. UE (macroscopic) and biopsy (microscopic) findings were collected from the distal esophagus, gastric pouch, and anastomotic site. Five diagnostic indices—sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve—were calculated to assess UE relative to biopsy.

The mean age was 34.7 ± 11.4 years; 75.3% were female. At the distal esophagus, normal UE findings increased from 75.7% at year 1 to 92.7% at year 3 (odds ratio [OR] = 0.32, p = 0.005). Gastric pouch abnormalities rose from 57.6% to 73.4% (OR = 2.03, p = 0.007). Anastomotic site abnormalities increased from 16.0% to 21.7% (OR = 1.46, p = 0.226). Biopsy findings for the distal esophagus showed a nonsignificant increase in abnormalities (OR = 1.54, p = 0.103), whereas gastric pouch abnormalities rose significantly (OR = 3.45, p < 0.001). Diagnostic accuracy varied by anatomical region and follow-up interval. UE reliably detected but poorly excluded distal esophageal disease. At the gastric pouch, UE could both identify and rule out disease with high accuracy. At the anastomotic site, UE findings closely mirrored biopsy results, making it a potential substitute when biopsy is unavailable.

Longer-term follow-up is needed post-OAGB. While UE effectively identifies distal esophageal disease, it may yield false negatives. By contrast, UE at the gastric pouch and anastomotic site reliably detects or excludes disease, offering a viable alternative to biopsy. Research of UE’s diagnostic accuracy at various time points in post-OAGB populations is required.

1. At the distal esophagus, the incidence of normal upper endoscopy (UE) findings improved significantly over time (75.7% to 92.7%), while the gastric pouch (57.6% to 73.4%) and anastomotic site (16.0% to 21.7%) showed increasing abnormalities.

2. Diagnostic accuracy varied by anatomical region and follow-up interval: UE reliably detected distal esophageal disease but struggled to exclude it, whereas it accurately identified and ruled out disease at the gastric pouch.

3. At the anastomotic site, UE findings closely mirrored biopsy results, indicating that UE can be a viable substitute for biopsy when the latter is unavailable.

## Full-text entities

- **Diseases:** mesenteric defects (MESH:D008639), malignancy (MESH:D009369), crypt abscess (MESH:D000038), Chronic inflammation (MESH:D007249), UE (MESH:D012141), Gastroesophageal reflux disease (MESH:D005764), BE (MESH:D001471), metabolic syndrome (MESH:D024821), eosinophilic esophagitis (MESH:D057765), fibrosis (MESH:D005355), H pylori infection (MESH:D016481), dysplasia (MESH:D015792), osteoarthritis (MESH:D010003), MBS (MESH:D008659), acanthosis (MESH:D000052), -related abnormalities (MESH:D000077733), esophagitis (MESH:D004941), metaplasia (MESH:D008679), Obesity (MESH:D009765), esophageal and gastric cancer (MESH:D013274), calculous cholecystitis (MESH:D002764), hyperemia (MESH:D006940), cardiovascular diseases (MESH:D002318), esophageal disease (MESH:D004935), excess weight loss (MESH:D015431), venous thrombosis (MESH:D020246), Ulceration (MESH:D014456), histopathological abnormalities (MESH:D000014), dyspeptic symptoms (MESH:D012816), carcinogenic (MESH:D011230), chronic gastritis (MESH:D005756), basal cell hyperplasia (MESH:D002280), HH (MESH:D006551), basal hyperplasia (MESH:D006965), ASMBS (MESH:C000719191), Gastric pouch abnormalities (MESH:D013272), obstructive sleep apnea (MESH:D020181), type 2 diabetes mellitus (MESH:D003924), mucosal abnormalities (MESH:D052016), BR (MESH:D001655), incompetent (MESH:D001022)
- **Chemicals:** bilirubin (MESH:D001663), paraffin (MESH:D010232), Enoxaparin (MESH:D017984), LA (MESH:D007811), methylene blue (MESH:D008751), Hematoxylin and eosin (-), H&amp;E (MESH:D006371), hematoxylin (MESH:D006416), eosin (MESH:D004801), alcohol (MESH:D000438), formalin (MESH:D005557)
- **Species:** Helicobacter pylori (species) [taxon 210], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12809904/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12809904/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12809904/full.md

---
Source: https://tomesphere.com/paper/PMC12809904